Introduction
CMV colitis is diagnosed by combining clinical suspicion with laboratory and tissue-based testing. Cytomegalovirus (CMV) is a common herpesvirus that can remain latent in the body and reactivate when immune defenses are weakened. When the virus infects the lining of the colon, it can damage epithelial cells, disrupt mucosal integrity, and cause inflammation or ulceration. Because these changes can resemble other inflammatory or infectious bowel diseases, diagnosis depends on more than symptoms alone.
Accurate diagnosis matters because treatment differs from that of bacterial colitis, inflammatory bowel disease, ischemic injury, or medication-related bowel inflammation. In many cases, the question is not simply whether CMV is present, but whether it is actively causing the colitis. For that reason, clinicians often rely on endoscopic biopsy and pathology, supported by blood or stool tests and the overall clinical picture. The diagnostic approach is especially important in people with weakened immune systems, where CMV can cause severe gastrointestinal disease and may require antiviral therapy.
Recognizing Possible Signs of the Condition
CMV colitis is usually suspected when a patient develops gastrointestinal symptoms in the setting of immune suppression or another condition that increases vulnerability to viral reactivation. Common symptoms include diarrhea, abdominal pain, fever, rectal bleeding, and weight loss. Some patients also have fatigue, dehydration, reduced appetite, or symptoms that suggest more extensive intestinal involvement.
The pattern of illness can be more informative than any single symptom. A person with advanced HIV, a transplant recipient taking immunosuppressive drugs, someone receiving chemotherapy, or a patient using high-dose corticosteroids may develop new diarrhea or bleeding that raises concern for opportunistic infection. In these settings, CMV can cause deep mucosal ulceration rather than mild superficial inflammation, and that destructive pattern may lead to more severe pain or blood loss.
Symptoms are not specific to CMV, which is why clinicians do not diagnose the disease on symptom description alone. However, the combination of lower gastrointestinal bleeding, persistent diarrhea, and immune compromise often prompts further investigation. In some patients, especially those who are very ill, symptoms may be subtle at first, and the diagnosis is only considered after routine treatment for presumed bacterial or inflammatory colitis fails.
Medical History and Physical Examination
The diagnostic process usually begins with a detailed history. Clinicians ask when symptoms started, how quickly they progressed, whether there is blood in the stool, whether the patient has fever or abdominal pain, and whether there has been recent weight loss or reduced intake. They also review recent travel, antibiotic use, hospitalizations, and exposure to enteric infections, because these can point toward other causes of colitis.
History-taking is particularly focused on immune status. Doctors look for organ transplantation, HIV infection, cancer therapy, autoimmune disease treated with biologic agents, recent steroid use, and other causes of impaired cell-mediated immunity. They also ask whether the patient has had prior CMV infection or CMV disease, since reactivation is common in those with prior exposure. In transplant patients, timing after transplantation and current immunosuppressive regimen may influence the level of suspicion.
The physical examination helps assess severity and complications. Doctors may check for abdominal tenderness, guarding, distention, fever, tachycardia, low blood pressure, or signs of dehydration. A rectal examination may identify gross blood or other clues to lower gastrointestinal bleeding. In severe disease, the exam may suggest systemic illness rather than isolated bowel inflammation. Although the physical findings are not diagnostic, they help determine how urgently further testing should be performed.
Diagnostic Tests Used for CMV Colitis
Confirmation usually requires direct evaluation of the colon, but several tests contribute to the diagnosis. Laboratory studies can show inflammation, anemia, or immune dysfunction, while imaging can reveal complications or exclude other causes. The most definitive evidence comes from tissue obtained during colonoscopy or sigmoidoscopy.
Laboratory tests often include a complete blood count, metabolic panel, liver tests, and inflammatory markers. A low hemoglobin level may reflect bleeding from ulcerated colonic mucosa. White blood cell abnormalities can indicate infection or immune suppression. Electrolyte disturbances and kidney injury may result from diarrhea and dehydration. These tests do not prove CMV colitis, but they help assess severity and guide management.
Blood testing may also include CMV polymerase chain reaction, or PCR, which measures viral DNA in the bloodstream. A positive blood PCR can support suspicion of active CMV infection, especially in immunocompromised patients, but it does not by itself confirm that the colon is the site of disease. Some patients with tissue-invasive colitis may have detectable viremia, while others do not. Serology for CMV antibodies is generally less useful for diagnosing active colitis because many adults have been exposed to CMV in the past and may remain antibody-positive without active disease.
Stool tests are often used to exclude other causes of colitis. Stool culture, ova and parasite testing, and assays for bacterial toxins or viral pathogens may help rule out alternative infections. Stool testing for CMV is not usually the main diagnostic method, because detection of viral material in stool does not reliably distinguish colonization or shedding from tissue-invasive disease. In practice, stool studies are most helpful when they identify a different cause of diarrhea.
Imaging tests such as computed tomography of the abdomen and pelvis may be obtained when symptoms are severe or when complications are suspected. Imaging can show colonic wall thickening, edema, inflammation, or, in rare cases, perforation and toxic megacolon. These findings are nonspecific, but they help define the extent of disease and guide urgent decisions about endoscopy or surgery. Imaging is particularly useful when abdominal pain is prominent or when clinicians need to assess whether the bowel wall is severely inflamed before proceeding with invasive testing.
Functional tests are not central to CMV colitis diagnosis in the way they are for some other gastrointestinal disorders, but clinicians may assess overall bowel function indirectly through symptom patterns, stool frequency, and nutritional status. In selected patients, fecal occult blood testing may support the presence of intestinal bleeding, although it does not identify the cause. The real diagnostic value lies in determining whether the intestine is functioning abnormally because of active mucosal injury.
Tissue examination is the key diagnostic step. Colonoscopy or flexible sigmoidoscopy allows direct visualization of the mucosa and collection of biopsy samples. Endoscopic findings may include large shallow ulcers, erosions, friability, or patchy inflammation, often in the colon or rectum. The appearance can resemble inflammatory bowel disease, ischemic injury, or other infections, so the visual pattern alone is not sufficient. Biopsy specimens are taken from the edge and base of ulcers, where infected cells are most likely to be found.
Pathologists examine the tissue under the microscope for signs of viral cytopathic effect. CMV-infected cells may appear enlarged with characteristic intranuclear inclusions, sometimes described as an “owl’s eye” appearance. Immunohistochemistry can detect CMV proteins in infected cells and improves sensitivity. Tissue PCR can also detect viral DNA in biopsy material, but interpretation is more nuanced because viral DNA may be present even when CMV is not the main cause of colitis. For this reason, clinicians usually give greatest weight to histology and immunostaining in the setting of compatible symptoms and endoscopic findings.
Interpreting Diagnostic Results
Doctors interpret results by matching laboratory, imaging, endoscopic, and pathology findings with the patient’s clinical context. A diagnosis of CMV colitis is strongest when a patient has compatible symptoms, visible colonic ulceration, and biopsy evidence of CMV-infected cells confirmed by immunohistochemistry or histology. This combination indicates that the virus is present in the inflamed tissue and is likely driving the disease process.
A positive blood PCR alone is usually not enough to establish CMV colitis. It indicates viral replication somewhere in the body, but it does not prove tissue-invasive disease in the colon. Similarly, a patient may have GI symptoms and nonspecific colitis on imaging without CMV being the cause. If biopsies are negative for CMV and another diagnosis is found, clinicians may rule out CMV colitis despite systemic viral positivity.
Negative pathology does not always end the investigation if suspicion remains high. Sampling error can occur because CMV may be patchy, and biopsy specimens may miss the infected area. When the first endoscopic evaluation is nondiagnostic but symptoms strongly suggest CMV, clinicians may repeat biopsy or sample a different segment of the colon. Interpretation therefore depends on both test quality and pretest probability.
Conditions That May Need to Be Distinguished
Several disorders can mimic CMV colitis, and distinguishing among them is part of the diagnostic process. In immunocompromised patients, bacterial colitis, Clostridioides difficile infection, herpes simplex infection, norovirus, and other opportunistic infections may cause overlapping symptoms. Stool studies and clinical history help narrow the differential diagnosis.
Inflammatory bowel disease, especially ulcerative colitis, can look similar endoscopically and histologically. CMV may also coexist with inflammatory bowel disease, particularly during severe flares or while patients are receiving immunosuppressive therapy. In those cases, doctors must decide whether CMV is merely present or is actually worsening the colitis. Biopsy evidence of viral cytopathic effect and immunostaining are important in this distinction.
Ischemic colitis is another major consideration, particularly in older adults or people with vascular disease, low blood pressure, or recent episodes of shock. Ischemic injury can produce abdominal pain and bloody diarrhea, and the colonic ulcers may resemble infectious disease. Medication-induced colitis, including injury from mycophenolate, checkpoint inhibitors, or nonsteroidal anti-inflammatory drugs, may also be considered depending on the patient’s treatment history. In each case, diagnosis depends on combining tissue findings with clinical context.
Factors That Influence Diagnosis
Several factors shape how CMV colitis is diagnosed. Immune status is one of the most important. A transplant recipient, a patient with advanced HIV, or someone receiving intensive immunosuppressive therapy is more likely to undergo early endoscopic biopsy because the threshold for suspecting CMV is lower. In otherwise healthy individuals, CMV colitis is less common and may be harder to suspect without strong evidence.
Severity of illness also matters. Patients with significant bleeding, severe diarrhea, abdominal distention, or signs of systemic infection may need faster imaging and urgent endoscopic evaluation. In critically ill patients, clinicians may limit the extent of endoscopy for safety reasons, which can make tissue sampling more challenging. Age can also influence the differential diagnosis, since older adults may have vascular disease or other conditions that mimic infectious colitis.
Related medical conditions can alter test interpretation. For example, a transplant patient may have low-level CMV viremia without colitis, while a patient with inflammatory bowel disease may have CMV detected in inflamed tissue even though the underlying flare is primarily autoimmune. The diagnostic question in those settings is not simply whether CMV is present, but whether it is clinically significant enough to warrant antiviral treatment.
Conclusion
CMV colitis is diagnosed through a stepwise process that begins with clinical suspicion and ends with confirmation from colon tissue. Symptoms such as diarrhea, abdominal pain, and bleeding are important clues, especially in patients with impaired immunity, but they are not specific enough to establish the diagnosis. Blood tests, stool studies, and imaging help assess severity and exclude other causes, while colonoscopy with biopsy provides the most reliable evidence of tissue-invasive disease.
Pathology is central because CMV colitis is defined by viral infection of the colon wall, not merely by exposure to the virus. The combination of endoscopic ulceration, microscopic viral inclusions, and immunohistochemical detection of CMV in biopsy tissue usually confirms the diagnosis. Careful interpretation is necessary because CMV can coexist with other bowel disorders or appear in the blood without causing colitis. By integrating clinical history, examination, and targeted testing, clinicians can identify CMV colitis accurately and distinguish it from other conditions with similar presentations.